TSS
PRLD icon

Two Sigma Securities’s Prelude Therapeutics PRLD Stock Holding History

Two Sigma Securities’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,922
Closed -$62.3K – 3225
2023
Q1 		$62.3K Buy
+10,922
New +$66.6K ﹤0.01% 2259

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Two Sigma Securities's PRLD Position: Q2 2023 in Review

Two Sigma Securities sold out of Prelude Therapeutics (PRLD) in Q2 2023, closing a stake of 10,922 shares — an estimated $62.3K sold.

Two Sigma Securities first reported a position in PRLD in Q1 2023 and held it in 1 quarter. The position peaked at $62.3K in Q1 2023. 55 funds tracked by Wall St. Rank hold PRLD as of Q2 2023.

  • Two Sigma Securities reported no remaining Prelude Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Securities sold 10,922 Prelude Therapeutics shares in Q2 2023, an estimated $62.3K.
  • Two Sigma Securities first reported a position in Prelude Therapeutics in Q1 2023 and held it in 1 quarter.
  • Two Sigma Securities's Prelude Therapeutics position peaked at $62.3K in Q1 2023.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2023.

Based on Two Sigma Securities's 13F filing for Q2 2023, filed 14 Aug 2023.